Astrazeneca Phar vs Divi's Lab.
Side-by-side stock comparison based on AI earnings call analysis
Which stock has stronger management signals?
Astrazeneca Phar currently has the stronger revenue growth signal.
Astrazeneca Phar and Divi's Lab. show active capex signals based on earnings call analysis.
No strong fundraising signal is currently visible for either company.
| Metric | Astrazeneca Phar | Divi's Lab. |
|---|---|---|
| Current Price | ₹7,193 | ₹8,602 |
| Market Cap | ₹18,538.75 Cr. | ₹2.28 L Cr. |
| Industry | Pharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology |
| P/E Ratio | 106.86 | 76.6 |
| ROE (%) | 23.29 | 16.53 |
| Debt/Equity | 0.13 | — |
| Sales Growth 5Y (%) | 22.84 | 8.67 |
| Profit Growth 5Y (%) | -15.74 | 37.43 |
| Promoter Holding (%) | 75 | 51.88 |
| Revenue Rank | Rank 2 | Rank 3 |
| Margin Rank | Rank 3 | Rank 3 |
| Signal | — | — |
| Capex | Yes | Yes |
| Fundraise | No information | No information |